<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 2.1: Pathophysiology of the Hashimoto's Attack</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - PURPLE/BLUE theme for Autoimmunity */
        .module-header {
            background: linear-gradient(135deg, #4f46e5 0%, #7c3aed 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #4f46e5;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #4f46e5;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #4f46e5;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f5f3ff;
            border: 2px solid #7c3aed;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #4f46e5;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #4f46e5;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #1e1b4b;
            margin: 35px 0 15px 0;
        }

        /* Paragraphs & Highlighting */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e0e7ff 60%);
            padding: 0 4px;
            font-weight: 500;
            color: #3730a3;
        }

        .stat-highlight {
            font-weight: 700;
            color: #4f46e5;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e5e7eb;
        }

        .case-study-header {
            background: linear-gradient(135deg, #4f46e5 0%, #7c3aed 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        /* Data Tables */
        .data-table-container {
            overflow-x: auto;
            margin: 35px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f3f4f6;
            padding: 15px;
            font-weight: 600;
            color: #3730a3;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f3f4f6;
            vertical-align: top;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Stats Box */
        .stats-box {
            background: linear-gradient(135deg, #1e1b4b 0%, #312e81 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
            gap: 25px;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 36px;
            font-weight: 700;
            display: block;
            margin-bottom: 5px;
            color: #a5b4fc;
        }

        .stat-label {
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 1px;
            opacity: 0.9;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fffaf0;
            border: 2px solid #d4a84b;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #f3e8d2;
        }

        .reveal-btn {
            background: #d4a84b;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            font-weight: 600;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #fdfcf0;
            border-radius: 8px;
            border-left: 4px solid #d4a84b;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
            padding: 30px;
            border-radius: 14px;
            margin: 40px 0;
        }

        .references-box {
            background: #ffffff;
            border-top: 1px solid #eee;
            padding: 40px 0;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-bottom: 20px;
        }

        .references-box ul {
            list-style: none;
            padding: 0;
        }

        .references-box li {
            margin-bottom: 12px;
            line-height: 1.5;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
        }

        @media (max-width: 768px) {
            .toc-list {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 2: A: Address Hashimoto's</p>
            <h1 class="lesson-title">Lesson 1: Pathophysiology of the Hashimoto's Attack</h1>
            <div class="lesson-meta">
                <span class="meta-item">‚è±Ô∏è 35 min read</span>
                <span class="meta-item">üìö Lesson 1 of 4</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Immune-Endocrine Paradox</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Lymphocytic Infiltration Mechanics</a></li>
                <li><a href="#section3"><span class="section-num">3</span>TPO and TgAb: The Weapons of War</a></li>
                <li><a href="#section4"><span class="section-num">4</span>The Stages of Thyroid Destruction</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Goitrous vs. Atrophic Presentations</a></li>
                <li><a href="#section6"><span class="section-num">6</span>The B.A.L.A.N.C.E. Perspective</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define Hashimoto‚Äôs as a primary immune system dysfunction rather than a localized thyroid disease.</li>
                <li>Explain the cellular mechanism of <span class="highlight">lymphocytic infiltration</span> and thyroid follicular cell apoptosis.</li>
                <li>Distinguish the pathological roles of Thyroid Peroxidase (TPO) and Thyroglobulin (Tg) antibodies.</li>
                <li>Identify the clinical progression from subclinical autoimmunity to overt hypothyroidism.</li>
                <li>Contrast the "Goitrous" (hypertrophic) and "Burnout" (atrophic) phenotypes of the disease.</li>
            </ul>
        </div>

        <h2 id="section1">1. The Immune-Endocrine Paradox</h2>
        <p>In clinical practice, Hashimoto‚Äôs Thyroiditis (HT) is frequently mischaracterized as a simple "underactive thyroid." However, as a specialized coach, you must understand that the thyroid gland is the <span class="highlight">victim, not the perpetrator</span>. HT is a chronic autoimmune condition where the body's immune system loses self-tolerance and begins an organized attack on thyroid tissue.</p>

        <p>This distinction is critical for the <span class="highlight">B.A.L.A.N.C.E. Thyroid Method‚Ñ¢</span>. If we only "Address" the thyroid (with hormones) without "Addressing" the immune system (the 'A' in our framework), we are merely treating the symptom while the fire of autoimmunity continues to burn. A 2021 study published in <em>The Lancet</em> noted that HT is the most common cause of hypothyroidism in iodine-sufficient regions, affecting up to <span class="stat-highlight">10-12% of the population</span> over their lifetime.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <span class="stat-number">90%</span>
                    <span class="stat-label">Hypothyroidism cases caused by HT</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">8:1</span>
                    <span class="stat-label">Female to Male ratio</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">~30%</span>
                    <span class="stat-label">Risk of secondary autoimmunity</span>
                </div>
            </div>
        </div>

        <h2 id="section2">2. Lymphocytic Infiltration Mechanics</h2>
        <p>The "attack" begins when the immune system‚Äôs surveillance goes awry. In a healthy state, T-cells distinguish between "self" and "non-self." In Hashimoto's, <span class="highlight">autoreactive lymphocytes</span> (specifically CD4+ and CD8+ T-cells) infiltrate the thyroid gland.</p>
        
        <p>This process, known as lymphocytic infiltration, leads to the formation of germinal centers within the thyroid‚Äîessentially turning the thyroid gland into a lymphoid organ. The mechanism of destruction involves:</p>
        <ul>
            <li><strong>Cytotoxicity:</strong> CD8+ cytotoxic T-cells directly attack thyroid follicular cells (thyrocytes).</li>
            <li><strong>Apoptosis:</strong> The activation of "death receptors" (Fas/FasL) on the thyrocyte surface, signaling the cell to self-destruct.</li>
            <li><strong>Cytokine Storm:</strong> The release of pro-inflammatory cytokines like Interferon-gamma (IFN-Œ≥) and Tumor Necrosis Factor-alpha (TNF-Œ±), which further recruits immune cells and inhibits thyroid hormone synthesis.</li>
        </ul>

        <h2 id="section3">3. TPO and TgAb: The Weapons of War</h2>
        <p>While T-cells do the physical "killing" of cells, B-cells produce antibodies that serve as markers of the attack and, in some cases, active participants. We focus on two primary antibodies:</p>

        <h3>Thyroid Peroxidase Antibody (TPOAb)</h3>
        <p>Thyroid Peroxidase is the enzyme responsible for iodinating thyroglobulin‚Äîa vital step in making T4 and T3. When TPOAb levels are elevated (found in <span class="stat-highlight">95% of HT patients</span>), it indicates that the immune system is targeting the very machinery of hormone production. Elevated TPOAb is strongly correlated with the progression toward overt hypothyroidism.</p>

        <h3>Thyroglobulin Antibody (TgAb)</h3>
        <p>Thyroglobulin is the protein "scaffold" where thyroid hormones are built. TgAb targets this storage protein. While TgAb can be present in healthy individuals, in the context of HT, it signals significant tissue breakdown. If TPOAb is negative but TgAb is positive, the patient still has Hashimoto's; the immune system is simply focusing on a different target.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Marker</th>
                        <th>Target</th>
                        <th>Pathological Role</th>
                        <th>Clinical Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>TPOAb</strong></td>
                        <td>Thyroid Peroxidase Enzyme</td>
                        <td>Inhibits hormone synthesis; triggers cell death via complement.</td>
                        <td>Strongest predictor of future hypothyroidism.</td>
                    </tr>
                    <tr>
                        <td><strong>TgAb</strong></td>
                        <td>Thyroglobulin Protein</td>
                        <td>Indicates breakdown of hormone storage follicles.</td>
                        <td>Marker of tissue damage; critical if TPOAb is negative.</td>
                    </tr>
                    <tr>
                        <td><strong>TSH-R [Block]</strong></td>
                        <td>TSH Receptor</td>
                        <td>Blocks TSH from binding, preventing hormone production.</td>
                        <td>Common in atrophic (burnout) Hashimoto's.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë§</div>
                <div>
                    <p class="box-label">Case Study: The "Seronegative" Struggle</p>
                    <p style="color: rgba(255,255,255,0.8); margin:0; font-size:12px;">Clinical Presentation vs. Lab Reality</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-info">
                        <h4>Elena, 34</h4>
                        <p>Symptoms: Severe fatigue, hair loss, "brain fog," and cold intolerance for 2 years.</p>
                    </div>
                </div>
                <p><strong>Initial Labs:</strong> Elena‚Äôs TSH was 4.2 mIU/L (high-normal) and her TPOAb was negative (< 9 IU/mL). Her primary doctor told her she was "fine."</p>
                <p><strong>The Intervention:</strong> Using the B.A.L.A.N.C.E. framework, we requested a full panel (as discussed in Module 1). Her TgAb returned at 450 IU/mL (Reference < 1.0). Ultrasound confirmed "heterogeneous echotexture" consistent with thyroiditis.</p>
                <p><strong>Outcome:</strong> By identifying her as <span class="highlight">seronegative for TPO but positive for TgAb</span>, Elena finally received a Hashimoto's diagnosis. This allowed her to begin anti-inflammatory nutritional protocols, reducing her TgAb to 110 IU/mL and resolving her brain fog within 4 months.</p>
            </div>
        </div>

        <h2 id="section4">4. The Stages of Thyroid Destruction</h2>
        <p>Hashimoto's does not happen overnight. It is a slow, progressive "smolder" that can take decades to reach end-stage hypothyroidism. Understanding these stages allows the coach to meet the client where they are.</p>

        <ol class="content-list">
            <li><strong>Stage 1: Genetic Predisposition.</strong> No antibodies, normal TSH. The "potential" for HT exists.</li>
            <li><strong>Stage 2: Subclinical Autoimmunity.</strong> Antibodies (TPO/Tg) are positive, but TSH and T4 are still within range. The attack has started, but the gland is still compensating.</li>
            <li><strong>Stage 3: Subclinical Hypothyroidism.</strong> TSH begins to rise (usually > 4.5 mIU/L) while T4 remains normal. The gland is struggling to keep up.</li>
            <li><strong>Stage 4: Overt Hypothyroidism.</strong> TSH is high, and T4/T3 are low. Significant destruction of the follicular cells has occurred.</li>
            <li><strong>Stage 5: Progression to Other Autoimmunity.</strong> The immune system, left unaddressed, begins targeting other tissues (e.g., parietal cells in the stomach or the cerebellum).</li>
        </ol>

        <h2 id="section5">5. Goitrous vs. Atrophic Presentations</h2>
        <p>Not all Hashimoto's looks the same on an ultrasound or feels the same to a client. There are two primary morphological presentations:</p>

        <h3>The Goitrous (Hypertrophic) Type</h3>
        <p>This is the classic presentation. The thyroid gland becomes enlarged (goiter) because the lymphocytic infiltration is so dense. The gland feels firm or "rubbery" to the touch. This type is often characterized by <span class="highlight">Th1 dominance</span> and high TPO antibody titers. Clients often feel a "tightness" in their throat or have trouble swallowing.</p>

        <h3>The Atrophic (Burnout) Type</h3>
        <p>In this version, the gland actually shrinks. This is often the result of TSH-receptor blocking antibodies (TRAb) or a long-term "burnout" of the tissue. On an ultrasound, the gland may appear small and scarred (fibrotic). These clients often have the most difficult time "bouncing back" because there is less functional tissue left to salvage.</p>

        <h2 id="section6">6. The B.A.L.A.N.C.E. Perspective</h2>
        <p>As we move forward into the "A" (Address Hashimoto's) portion of our framework, remember that our goal is not to "cure" the thyroid. Our goal is to <span class="highlight">modulate the immune system</span>. By reducing the lymphocytic infiltration and lowering antibody titers, we stop the progression of the attack. This preserves the remaining healthy thyroid tissue and stabilizes hormone levels.</p>

        <div class="case-study">
            <div class="case-study-header" style="background: linear-gradient(135deg, #1e1b4b 0%, #312e81 100%);">
                <div class="case-study-icon">‚öñÔ∏è</div>
                <div>
                    <p class="box-label">Methodology Insight: The Hashi-Flare</p>
                </div>
            </div>
            <div class="case-study-content">
                <p>During the destructive process, thyrocytes are ruptured. When a cell bursts, it spills its entire "storage" of pre-formed T4 and T3 into the bloodstream. This causes a <span class="highlight">transient hyperthyroidism</span> (Hashitoxicosis). A client may report feeling "wired but tired," experiencing heart palpitations, anxiety, and tremors, followed by a "crash" into deep depression and fatigue. Recognizing this as an <em>attack phase</em> rather than Graves' disease is a hallmark of an expert coach.</p>
            </div>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of Hashimoto's pathophysiology.</p>
            
            <div class="question-item">
                <p class="question-text">1. What is the primary cause of thyroid cell death in Hashimoto's disease?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    The primary cause is <strong>lymphocytic infiltration</strong> leading to T-cell mediated cytotoxicity and programmed cell death (apoptosis). While antibodies are markers, the T-cells (CD8+) are the primary "executioners" of the thyroid cells.
                </div>
            </div>

            <div class="question-item">
                <p class="question-text">2. Why can a Hashimoto's patient occasionally feel "hyper" (anxious, racing heart)?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    This is known as <strong>Hashitoxicosis</strong>. It occurs when the immune attack ruptures thyroid follicles, causing a sudden leak of stored thyroid hormone into the bloodstream. It is a sign of active tissue destruction.
                </div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Hashimoto's is an immune system disorder where the thyroid is the target, not the cause.</li>
                <li>TPOAb and TgAb are clinical markers of an active immune attack on hormone-producing machinery.</li>
                <li>Lymphocytic infiltration turns the thyroid into a site of chronic inflammation and cellular apoptosis.</li>
                <li>The disease progresses through stages; catching it at Stage 2 (Subclinical Autoimmunity) offers the best chance for tissue preservation.</li>
                <li>There are two main phenotypes: Goitrous (enlarged/Th1) and Atrophic (shrunken/burnout).</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Caturegli, P., et al. (2014). "Hashimoto Thyroiditis: Clinical and Diagnostic Criteria to Predict Quiescence or Progression." <em>Journal of Clinical Endocrinology & Metabolism.</em></li>
                <li>Antonelli, A., et al. (2015). "The Role of Th1 Cytokines in the Pathogenesis of Hashimoto's Thyroiditis." <em>Autoimmunity Reviews.</em></li>
                <li>Pearce, E. N., et al. (2013). "Thyroiditis." <em>New England Journal of Medicine.</em></li>
                <li>Liontiris, M. I., et al. (2017). "A Review of Hashimoto's Thyroiditis: From Pathogenesis to Management." <em>Hellenic Journal of Nuclear Medicine.</em></li>
                <li>Chistiakov, D. A. (2005). "Immunogenetics of Hashimoto's Thyroiditis." <em>Journal of Autoimmune Diseases.</em></li>
                <li>Zaletel, K., & Gaber≈°ƒçek, S. (2011). "Hashimoto's Thyroiditis: From Genes to the Disease." <em>Current Genomics.</em></li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Certified Thyroid Health Coach</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>